GDF15 Induces an Aversive Visceral Malaise State that Drives Anorexia and Weight Loss
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The anorectic and weight-suppressive effects of growth differentiation factor-15 (GDF15) are attracting considerable attention for treating obesity. Current experiments in rats investigate whether GDF15 induces an aversive visceral malaise-based state that mediates its acute anorectic effect and, through aversion conditioning, exerts longer-term anorexia. Visceral malaise, conditioned affective food responses (taste reactivity), gastric emptying (GE), food intake, and body weight are evaluated after acute and chronic systemic dosing of GDF15 or long-acting Fc-GDF15. Pica, a marker of visceral malaise, is present at all anorectic GDF15 doses. Moreover, malaise induced by GDF15 does not decline over time, suggesting the lack of an improved tolerance after prolonged exposure. One association between GDF15 and novel food conditions a disgust/aversive response that persists beyond GDF15 acute action. Delayed GE is not a requirement for GDF15-induced anorexia. Clinical studies are required to evaluate whether GDF15's aversive-state-based anorexia will be contraindicated as an obesity treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“A point of comparison is provided by the extensive clinical and pre-clinical literature describing the anorexia-driven body weight loss resulting from long-acting GLP1R agonist treatment (Müller et al., 2019).”
BackgroundSelf-citationBerridge, K. C., & Kringelbach, M. L. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.018 · Cited by 1,730
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · cited 1×
“While GLP-1R agonist dose titration has been relatively successful in reducing the prevalence of its visceral malaise adverse events (Nauck et al., 2009; Neumiller and Campbell, 2009), it is as yet unknown whether the same may be true for GDF15.”
BackgroundGFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates
Mullican, S. E., Lin-Schmidt, X., Chin, C.-N., Chavez, J. A., Furman, J. L., Armstrong, A. A., Beck, S. C., South, V. J., Dinh, T. Q., Cash-Mason, T. D., et al. (2017) · Nature Medicine · doi:10.1038/nm.4392 · Cited by 774
Berridge, K. (2000) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(99)00072-x · Cited by 721 · cited 3×
“The response components comprising hedonic and disgust/aversive categories have been described in detail elsewhere (Berridge, 2000, 2018; Grill and Norgren, 1978b; Spector et al., 1988).”
BackgroundMethodThe metabolic effects of GDF15 are mediated by the orphan receptor GFRAL
Emmerson, P. J., Wang, F., Du, Y., Liu, Q., Pickard, R. T., Gonciarz, M. D., Coskun, T., Hamang, M. J., Sindelar, D. K., Ballman, K. K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4393 · Cited by 675 · cited 10×
“Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond.”
BackgroundInfluentialSelf-citationGFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand
Yang, L., Chang, C.-C., Sun, Z., Madsen, D., Zhu, H., Padkjær, S. B., Wu, X., Huang, T., Hultman, K., Paulsen, S. J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4394 · Cited by 668 · cited 11×
“Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond.”
BackgroundInfluentialNon-Homeostatic Body Weight Regulation Through a Brainstem-Restricted Receptor for GDF15
Hsu, J.-Y., Crawley, S., Chen, M., Ayupova, D. A., Lindhout, D. A., Higbee, J., Kutach, A., Joo, W., Gao, Z., Fu, D., et al. (2017) · Nature · doi:10.1038/nature24042 · Cited by 616
Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1
Johnen, H., Lin, S., Kuffner, T., Brown, D. A., Tsai, V. W.-W., Bauskin, A. R., Wu, L., Pankhurst, G., Jiang, L., Junankar, S., et al. (2007) · Nature Medicine · doi:10.1038/nm1677 · Cited by 612 · cited 2×
“with the severity of the anorexia/cachexia in both oncology patients and in rodent models, strongly suggesting GDF15’s clinical relevance as a mediator of the anorexia-cachexia syndrome (Bauskin et al., 2006; Borner et al., 2017; Brown et al., 2003; Johnen et al., 2007; Tsai et al., 2018b; Welsh et al., 2003).”
BackgroundGrill, H. J., & Norgren, R. (1978) · Brain Research · doi:10.1016/0006-8993(78)90569-3 · Cited by 588
Self-citationGenetic identification of a neural circuit that suppresses appetite
Carter, M. E., Soden, M. E., Zweifel, L. S., & Palmiter, R. D. (2013) · Nature · doi:10.1038/nature12596 · Cited by 587 · cited 1×
“Recent work from the Palmiter lab (Carter et al., 2013; Chen et al., 2018) provides a range of support and considerable molecular depth for a key role of a unique subpopulation of lateral PBN neurons expressing calcitonin gene-related peptide (CGRP) that project to the central nucleus of amygdala and bed nucleus neuro…”
Backgroundvan Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537
GDF15 Provides an Endocrine Signal of Nutritional Stress in Mice and Humans
Patel, S., Alvarez-Guaita, A., Melvin, A., Rimmington, D., Dattilo, A., Miedzybrodzka, E. L., Cimino, I., Maurin, A.-C., Roberts, G. P., Meek, C. L., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.12.016 · Cited by 509 · cited 3×
“The food affective response change mediated by the associative effect of GDF15-induced visceral malaise was expressed 2–3 days after acute dosing when the acute anorectic effects were no longer present and circulating GDF15 levels were no longer elevated (Patel et al., 2019).”
BackgroundSelf-citationLarge-Scale Delineation of Secreted Protein Biomarkers Overexpressed in Cancer Tissue and Serum
Welsh, J. B., Sapinoso, L. M., Kern, S. G., Brown, D. A., Liu, T., Bauskin, A. R., Ward, R. L., Hawkins, N. J., Quinn, D. I., Russell, P. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530278100 · Cited by 503 · cited 1×
“with the severity of the anorexia/cachexia in both oncology patients and in rodent models, strongly suggesting GDF15’s clinical relevance as a mediator of the anorexia-cachexia syndrome (Bauskin et al., 2006; Borner et al., 2017; Brown et al., 2003; Johnen et al., 2007; Tsai et al., 2018b; Welsh et al., 2003).”
BackgroundGLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427
Kanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273 · cited 1×
“Studies aimed at identifying the neurobehavioral processes mediating GLP1R agonist’s anorectic effect show clearly that, in addition to triggering a visceral-malaise-based aversive state (Kanoski et al., 2012; Kinzig et al., 2002; Thiele et al., 1997), other mediating processes also contribute to its food intake suppr…”
BackgroundEvolving Concepts of Emotion and Motivation
Berridge, K. C. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01647 · Cited by 273 · cited 1×
“The response components comprising hedonic and disgust/aversive categories have been described in detail elsewhere (Berridge, 2000, 2018; Grill and Norgren, 1978b; Spector et al., 1988).”
MethodGDF15 induces anorexia through nausea and emesis
Borner, T., Shaulson, E. D., Ghidewon, M. Y., Barnett, A. B., Horn, C. C., Doyle, R. P., Grill, H. J., Hayes, M. R., & De Jonghe, B. C. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.004 · Cited by 255 · cited 1×
“Further, recent work indicates that acute GDF15 administration is capable of inducing emesis in the musk shrew, a mammalian model capable of vomiting (Borner et al., 2020).”
BackgroundSelf-citationRole of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer
Bauskin, A. R., Brown, D. A., Kuffner, T., Johnen, H., Luo, X. W., Hunter, M., & Breit, S. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4067 · Cited by 251 · cited 1×
“with the severity of the anorexia/cachexia in both oncology patients and in rodent models, strongly suggesting GDF15’s clinical relevance as a mediator of the anorexia-cachexia syndrome (Bauskin et al., 2006; Borner et al., 2017; Brown et al., 2003; Johnen et al., 2007; Tsai et al., 2018b; Welsh et al., 2003).”
BackgroundLong-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys
Xiong, Y., Walker, K., Min, X., Hale, C., Tran, T., Komorowski, R., Yang, J., Davda, J., Nuanmanee, N., Kemp, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8732 · Cited by 236 · cited 2×
“The highest dose of GDF15 significantly slowed GE, consistent with one report in the literature that used a 5-fold higher dose (Xiong et al., 2017).”
BackgroundResultGoldstone, A. P., Miras, A. D., Scholtz, S., Jackson, S., Neff, K. J., Pénicaud, L., Geoghegan, J., Chhina, N., Durighel, G., Bell, J. D., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2665 · Cited by 121 · cited 1×
“, 2017), and reduced feeding motivation (Alhadeff et al., 2017; Goldstone et al., 2016; van Bloemendaal et al., 2014).”
Alhadeff, A. L., & Grill, H. J. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00179.2014 · Cited by 111 · cited 1×
“, 2014), reduced food seeking (Alhadeff and Grill, 2014; Ong et al., 2017), and reduced feeding motivation (Alhadeff et al.”
BackgroundSelf-citationAlhadeff, A. L., Mergler, B. D., Zimmer, D. J., Turner, C. A., Reiner, D. J., Schmidt, H. D., Grill, H. J., & Hayes, M. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.246 · Cited by 102 · cited 2×
“, 2017), and reduced feeding motivation (Alhadeff et al., 2017; Goldstone et al., 2016; van Bloemendaal et al., 2014).”
BackgroundSelf-citation
Cited by
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease
Wang, D., Day, E. A., Townsend, L. K., Djordjevic, D., Jørgensen, S. B., & Steinberg, G. R. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00529-7 · Cited by 516
Benichou, O., Coskun, T., Gonciarz, M. D., Garhyan, P., Adams, A. C., Du, Y., Dunbar, J. D., Martin, J. A., Mather, K. J., Pickard, R. T., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.12.011 · Cited by 115
Brain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
Ghidewon, M., Wald, H. S., McKnight, A. D., De Jonghe, B. C., Breen, D. M., Alhadeff, A. L., Borner, T., & Grill, H. J. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14663 · Cited by 51
Self-citation
Metadata
- Authors
- Borner, T., Wald, H. S., Ghidewon, M. Y., Zhang, B., Wu, Z., De Jonghe, B. C., Breen, D., & Grill, H. J.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 31
- Issue
- 3
- Pages
- 107543
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W3017224205
- Cited by
- 100
- References
- 23
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.